Clinical trial
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
NCT00211224 · King's College London, Other · Terminated
Key facts
| NCT number | NCT00211224 |
|---|---|
| Title | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) |
| Official title | Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes) |
| Lead sponsor | King's College London, Other |
| Collaborators | Assistance Publique - Hôpitaux de Paris University of Ulm Aventis Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple System Atrophy, Progressive Supranuclear Palsy |
| Intervention type | Drug |
| Interventions | Riluzole |
| Enrollment | 800 |
| Start date | Apr 1, 2000 |
| Completion | Nov 1, 2004 |
| First posted | Sep 21, 2005 |
| Last update posted | Dec 15, 2005 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: